In 1986, Hoofnagle and coworkers reported the initial use of recombinant interferon alfa to treat patients with non-A, non-B hepatitis, demonstrating improvement in serum ALT levels in most patients. Over the ensuing decade, hepatitis C virus was identified cause of non-A, non-B hepatitis and molecular techniques were applied to test HCV RNA response during therapy, and it became apparent that the majority of persons treated with interferon alfa did not achieve HCV eradication (Sustained Virologic Response, SVR). Further, the poor safety and tolerability of interferon alfa prohibited treatment of many HCV-infected patients. In 1995, several studies demonstrated that the addition of the guanosine nucleoside analogue ribavirin to interferon led to higher SVR rates despite the lack of HCV RNA reduction with ribavirin monotherapy. In 2003, the first report of a potent direct acting antiviral (DAA), an inhibitor of the HCV NS3/4A protease known as BILN 2061, was published, and, in 2011, two HCV NS3/4A protease inhibitors, telaprevir and boceprevir, entered clinical practice as part of “triple therapy” with interferon/ribavirin, and, while toxicity limited their effectiveness, the DAA era was launched. In 2012, proof of HCV eradication by the interferon-free, combination of a HCV NS3/4A protease inhibitor and a NS5A inhibitor was published. In 2015, multiple, interferon-free, combinations of DAAs targeting HCV nonstructural proteins (e.g.,NS3/4A protease, NS5B polymerase and NS5A) have been approved by regulatory authorities. Remarkably, 12 weeks of treatment with these DAA regimens can deliver high rates of HCV cure (> 95%) with minimal adverse effects in diverse range of patients including those with HIV coinfection and decompensated liver disease. In this era, historical barriers to HCV cure linked to the necessity for interferon alfa have been overcome. In their place, new challenges have emerged including the cure of persons with HCV genotype 3 infection and those with advanced liver disease among whom SVR rates are lower than observed in other patient groups as well as the specter of HCV drug resistance in persons who fail to achieve HCV eradication following treatment. However, the greatest challenge will be the need to rapidly translate these remarkable advances in HCV therapeutics to the large global community of persons chronically infected with hepatitis C to prevent the development of life-threatening complications of HCV disease.